Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Tarsus Pharmaceuticals, Inc. | exhibit322202010k.htm |
| EX-31.2 - EX-31.2 - Tarsus Pharmaceuticals, Inc. | exhibit312202010k.htm |
| EX-31.1 - EX-31.1 - Tarsus Pharmaceuticals, Inc. | exhibit311202010k.htm |
| EX-23.1 - EX-23.1 - Tarsus Pharmaceuticals, Inc. | exhibit231202010k.htm |
| EX-4.2 - EX-4.2 - Tarsus Pharmaceuticals, Inc. | exhibit42202010k.htm |
| 10-K - 10-K - Tarsus Pharmaceuticals, Inc. | tars-20201231.htm |
Exhibit 32.1
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Tarsus Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bobak Azamian, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and | |||||||||||||||||||||||||
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. | |||||||||||||||||||||||||
Date: March 31, 2021 | By: | /s/ Bobak Azamian, M.D., Ph.D. | |||||||||||||||||||||
Bobak Azamian, M.D., Ph.D. | |||||||||||||||||||||||
President and Chief Executive Officer | |||||||||||||||||||||||
(Principal Executive Officer) | |||||||||||||||||||||||